Antheia is the next-generation pharmaceutical ingredient producer with a mission to end drug shortages. Using advanced biosynthesis and fermentation technology, Antheia’s biomanufacturing platform enables rapid, efficient, agile, and on-demand production of key starting materials (KSMs) and active pharmaceutical ingredients (APIs) that are critical to public health. The firm believes its flexible approach supports the needs of a growing society and improves global access to essential medicines.

Founded in 2015, Antheia has grown into a commercial-stage company with its first product to market, an active customer pipeline, and near-term product launches. Dr. Christina Smolke, the company's co-founder and CEO, details her company's value proposition with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.